BioCardia to Present at the LD Micro Virtual Invitational Conference on June 8, 2021
BioCardia, Inc. (Nasdaq: BCDA) announced that CEO Peter Altman will present a corporate overview at the LD Micro Virtual Invitational Conference from June 8-10.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCardia, Inc. (Nasdaq: BCDA) announced that CEO Peter Altman will present a corporate overview at the LD Micro Virtual Invitational Conference from June 8-10. His presentation is scheduled for June 8 at 4:30 PM ET on Track 3. Investors can register to watch the presentation online. BioCardia is focused on developing regenerative biologic therapies for cardiovascular and pulmonary diseases, with key products like CardiAMP™ cell therapies and various delivery systems.
Details
News Market Reaction – BCDA
The recorded move for BCDA in the trading session of this news was +3.37%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, announced today that Chief Executive Officer Peter Altman will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10.
Mr. Altman will deliver his corporate presentation on June 8 at 4:30pm ET, Track 3.
Investors can register to watch the presentation here.
Investors interested in scheduling a meeting with management should contact assistant@ldmicro.com.
About BioCardia®
BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and pulmonary disease. CardiAMP™ autologous and NK1R+ allogeneic cell therapies are the Company’s biotherapeutic product candidates in clinical development. The Company's current products include the Helix™ transendocardial delivery system, the Morph® steerable guide and sheath catheter portfolio and the AVANCE™ steerable introducer family. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and development support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information, visit www.BioCardia.com.
INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@BioCardia.com
(650) 226-0120
MEDIA CONTACT:
Michelle McAdam, Chronic Communications, Inc.
michelle@chronic-comm.com
(310) 545-6654
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.